Biogen Inc. shares fell after additional data from a mid-stage study of its Alzheimer’s drug diranersen failed to show convincing evidence of benefit, according to Bloomberg.
A deeper dive into the results found hints of improvement in some areas.
STOCKS | Biogen Shares Slide After Alzheimer’s Diranersen Tau Trial Data Disappoints
2026-07-14 14:50:27
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
贵金属 | 霍尔木兹袭击增多致油价飙升
